Multiple Myeloma: Diagnosis and Treatment

Mayo Clinic Proceedings

Volumn 91, Issue 1, 2016, Pages 101-119

  Rajkumar, S Vincent ^a   Kumar, Shaji ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CARFILZOMIB; CYCLOPHOSPHAMIDE; DARATUMUMAB; DEXAMETHASONE; DOXORUBICIN; ELOTUZUMAB; ISATUXIMAB; IXAZOMIB; LENALIDOMIDE; MELPHALAN; PANOBINOSTAT; POMALIDOMIDE; PREDNISONE; THALIDOMIDE; TUMOR MARKER; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; PARAPROTEIN;

ACUTE KIDNEY FAILURE; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE LESION; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONSOLIDATION CHEMOTHERAPY; DISEASE ACTIVITY; FRAIL ELDERLY; HIGH RISK PATIENT; HUMAN; HYPERCALCEMIA; HYPERVISCOSITY SYNDROME; INDUCTION CHEMOTHERAPY; INFECTION PREVENTION; KIDNEY DISEASE; MAINTENANCE THERAPY; MOLECULAR DIAGNOSIS; MULTIPLE MYELOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PATIENT CARE; PRACTICE GUIDELINE; PROGRESSION FREE SURVIVAL; RADIODIAGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SURVIVAL TIME; CLASSIFICATION; DISEASE MANAGEMENT; PROGNOSIS; TUMOR VOLUME;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; DISEASE MANAGEMENT; HUMANS; MULTIPLE MYELOMA; MYELOMA PROTEINS; PROGNOSIS; TUMOR BURDEN;

EID: 84952845340     PISSN: 00256196     EISSN: 19425546     Source Type: Journal    
DOI: 10.1016/j.mayocp.2015.11.007     Document Type: Review

References (131)

1. S.V. Rajkumar, M.A. Dimopoulos, A. Palumbo, and et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma Lancet Oncol 15 12 2014 e538 e548
2. S.V. Rajkumar Multiple myeloma: 2014 update on diagnosis, risk-stratification, and management Am J Hematol 89 10 2014 999 1009
3. R.A. Kyle, T.M. Therneau, S.V. Rajkumar, D.R. Larson, M.F. Plevak, and L.J. Melton III Incidence of multiple myeloma in Olmsted County, Minnesota: trend over 6 decades Cancer 101 11 2004 2667 2674
4. O. Landgren, G. Gridley, I. Turesson, and et al. Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States Blood 107 3 2006 904 906
5. O. Landgren, B.I. Graubard, J.A. Katzmann, and et al. Racial disparities in the prevalence of monoclonal gammopathies: a population-based study of 12,482 persons from the National Health and Nutritional Examination Survey Leukemia 28 7 2014 1537 1542
6. R.A. Kyle, M.A. Gertz, T.E. Witzig, and et al. Review of 1027 patients with newly diagnosed multiple myeloma Mayo Clin Proc 78 1 2003 21 33
7. R.A. Kyle, T.M. Therneau, S.V. Rajkumar, and et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance N Engl J Med 346 8 2002 564 569
8. R.A. Kyle, T.M. Therneau, S.V. Rajkumar, and et al. Prevalence of monoclonal gammopathy of undetermined significance N Engl J Med 354 13 2006 1362 1369
9. A. Dispenzieri, J.A. Katzmann, R.A. Kyle, and et al. Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study [published correction appears in Lancet. 2010;376(9738):332] Lancet 375 9727 2010 1721 1728
10. O. Landgren, R.A. Kyle, R.M. Pfeiffer, and et al. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study Blood 113 22 2009 5412 5417
11. R.A. Kyle, E.D. Remstein, T.M. Therneau, and et al. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma N Engl J Med 356 25 2007 2582 2590
12. Myeloma Trialists' Collaborative Group Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials J Clin Oncol 16 12 1998 3832 3842
13. M. Attal, J.L. Harousseau, A.M. Stoppa, et al. Intergroupe Français du Myélome A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma N Engl J Med 335 2 1996 91 97
14. J.A. Child, G.J. Morgan, F.E. Davies, et al. Medical Research Council Adult Leukaemia Working Party High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma N Engl J Med 348 19 2003 1875 1883
15. S. Singhal, J. Mehta, R. Desikan, and et al. Antitumor activity of thalidomide in refractory multiple myeloma [published correction appears in N Engl J Med. 2000;342(5):364] N Engl J Med 341 21 1999 1565 1571
16. P.G. Richardson, B. Barlogie, J. Berenson, and et al. A phase 2 study of bortezomib in relapsed, refractory myeloma N Engl J Med 348 26 2003 2609 2617
17. P.G. Richardson, R.L. Schlossman, E. Weller, and et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma Blood 100 9 2002 3063 3067
18. S.K. Kumar, S.V. Rajkumar, A. Dispenzieri, and et al. Improved survival in multiple myeloma and the impact of novel therapies Blood 111 5 2008 2516 2520
19. S.K. Kumar, A. Dispenzieri, M.Q. Lacy, and et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients Leukemia 28 5 2014 1122 1128
20. K.D. Short, S.V. Rajkumar, D. Larson, and et al. Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma Leukemia 25 6 2011 906 908
21. J.A. Katzmann, A. Dispenzieri, R. Kyle, and et al. Elimination of the need for urine studies in the screening algorithm for monoclonal gammopathies by using serum immunofixation and free light chain assays Mayo Clin Proc 81 12 2006 1575 1578
22. S.S. Chawla, S.K. Kumar, A. Dispenzieri, and et al. Clinical course and prognosis of non-secretory multiple myeloma Eur J Haematol 95 1 2015 57 64
23. J.C. Regelink, M.C. Minnema, E. Terpos, and et al. Comparison of modern and conventional imaging techniques in establishing multiple myeloma-related bone disease: a systematic review Br J Haematol 162 1 2013 50 61
24. G.D. Roodman Pathogenesis of myeloma bone disease Leukemia 23 3 2009 435 441
25. J. Hillengass, K. Fechtner, M.A. Weber, and et al. Prognostic significance of focal lesions in whole-body magnetic resonance imaging in patients with asymptomatic multiple myeloma J Clin Oncol 28 9 2010 1606 1610
26. S. Kumar, R. Fonseca, R.P. Ketterling, and et al. Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics Blood 119 9 2012 2100 2105
27. A.M. Rajan, and S.V. Rajkumar Interpretation of cytogenetic results in multiple myeloma for clinical practice Blood Cancer J 5 2015 e365
28. W.M. Kuehl, and P.L. Bergsagel Multiple myeloma: evolving genetic events and host interactions Nat Rev Cancer 2 3 2002 175 187
29. P.L. Bergsagel, and W.M. Kuehl Chromosome translocations in multiple myeloma Oncogene 20 40 2001 5611 5622
30. R. Fonseca, R.J. Bailey, G.J. Ahmann, and et al. Genomic abnormalities in monoclonal gammopathy of undetermined significance Blood 100 4 2002 1417 1424
31. S. Seidl, H. Kaufmann, and J. Drach New insights into the pathophysiology of multiple myeloma Lancet Oncol 4 9 2003 557 564
32. S.J. Russell, and S.V. Rajkumar Multiple myeloma and the road to personalised medicine Lancet Oncol 12 7 2011 617 619
33. B.G. Durie, and S.E. Salmon A clinical staging system for multiple myeloma: correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival Cancer 36 3 1975 842 854
34. P.R. Greipp, J. San Miguel, B.G. Durie, and et al. International staging system for multiple myeloma J Clin Oncol 23 15 2005 3412 3420
35. P.N. Hari, M.J. Zhang, V. Roy, and et al. Is the international staging system superior to the Durie-Salmon staging system? a comparison in multiple myeloma patients undergoing autologous transplant Leukemia 23 8 2009 1528 1534
36. S.K. Kumar, J.R. Mikhael, F.K. Buadi, and et al. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines Mayo Clin Proc 84 12 2009 1095 1110
37. A. Palumbo, H. Avet-Loiseau, S. Oliva, and et al. Revised International Staging System for Multiple Myeloma: a report from International Myeloma Working Group J Clin Oncol 33 26 2015 2863 2869
38. J.R. Mikhael, D. Dingli, V. Roy, and et al. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013 Mayo Clin Proc 88 4 2013 360 376
39. R.A. Kyle, and S.V. Rajkumar Multiple myeloma [published correction appears in N Engl J Med. 2005;352(11):1163] N Engl J Med 351 18 2004 1860 1873
40. S.V. Rajkumar, E. Blood, D. Vesole, R. Fonseca, and P.R. Greipp Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group J Clin Oncol 24 3 2006 431 436
41. S.V. Rajkumar, L. Rosiñol, M. Hussein, and et al. Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma J Clin Oncol 26 13 2008 2171 2177
42. S.V. Rajkumar, S. Jacobus, N.S. Callander, et al. Eastern Cooperative Oncology Group Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial [published correction appears in Lancet Oncol. 2010;11(1):14] Lancet Oncol 11 1 2010 29 37
43. J.L. Harousseau, M. Attal, X. Leleu, and et al. Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study Haematologica 91 11 2006 1498 1505
44. T. Facon, J.Y. Mary, C. Hulin, et al. Intergroupe Francophone du Myélome Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial Lancet 370 9594 2007 1209 1218
45. C. Hulin, T. Facon, P. Rodon, and et al. Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial J Clin Oncol 27 22 2009 3664 3670
46. J.F. San Miguel, R. Schlag, N.K. Khuageva, et al. VISTA Trial Investigators Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma N Engl J Med 359 9 2008 906 917
47. M.V. Mateos, A. Oriol, J. Martínez-López, and et al. Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial Lancet Oncol 11 10 2010 934 941
48. A. Palumbo, S. Bringhen, D. Rossi, and et al. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial J Clin Oncol 28 34 2010 5101 5109
49. M. Cavo, P. Tacchetti, F. Patriarca, et al. GIMEMA Italian Myeloma Network Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study Lancet 376 9758 2010 2075 2085
50. C.B. Reeder, D.E. Reece, V. Kukreti, and et al. Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial Leukemia 23 7 2009 1337 1341
51. S. Kumar, I. Flinn, P.G. Richardson, and et al. Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma Blood 119 19 2012 4375 4382
52. P.G. Richardson, E. Weller, S. Lonial, and et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma Blood 116 5 2010 679 686
53. B. Barlogie, E. Anaissie, F. van Rhee, and et al. Incorporating bortezomib into upfront treatment for multiple myeloma: early results of Total Therapy 3 Br J Haematol 138 2 2007 176 185
54. F. van Rhee, J. Szymonifka, E. Anaissie, and et al. Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapy Blood 116 8 2010 1220 1227
55. D.S. Siegel, T. Martin, M. Wang, and et al. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma Blood 120 14 2012 2817 2825
56. S. Bringhen, M.T. Petrucci, A. Larocca, and et al. Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study Blood 124 1 2014 63 69
57. A.J. Jakubowiak Evolution of carfilzomib dose and schedule in patients with multiple myeloma: a historical overview Cancer Treat Rev 40 6 2014 781 790
58. P.G. Richardson, D.S. Siegel, R. Vij, and et al. Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study Blood 123 12 2014 1826 1832
59. J.J. Shah, E.A. Stadtmauer, R. Abonour, and et al. Phase I/II dose expansion of a multi-center trial of carfilzomib and pomalidomide with dexamethasone (Car-Pom-d) in patients with relapsed/refractory multiple myeloma [abstract] Blood 122 21 2013 690
60. T. Facon, M.A. Dimopoulos, A. Dispenzieri, and et al. Initial phase 3 results of the First (Frontline Investigation Of Lenalidomide + Dexamethasone Versus Standard Thalidomide) Trial (MM-020/IFM 07 01) in newly diagnosed multiple myeloma (NDMM) patients (Pts) ineligible for stem cell transplantation (SCT) Blood 122 2013 2
61. Durie B, Hoering A, Rajkumar SV, et al. Bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT): results of the randomized phase III trial SWOG S0777 [ASH Annual Meeting Abstracts 2015, abstract 25]. American Society of Hematology website. https://ash.confex.com/ash/2015/webprogram/Paper79014.html. Accessed November 10, 2015.
62. Moreau P, Hulin C, Macro M, et al. Bortezomib, thalidomide and dexamethasone (VTD) is superior to bortezomib, cyclophosphamide and dexamethasone (VCD) prior to autologous stem cell transplantation for patients with de novo multiple myeloma: results of the prospective IFM 2013-04 trial [ASH Annual Meeting Abstracts 2015, abstract 393]. American Society of Hematology website. https://ash.confex.com/ash/2015/webprogram/Paper81103.html. Accessed November 10, 2015.
63. Attal M, Lauwers-Cances V, Hulin C, et al. Autologous transplantation for multiple myeloma in the era of new drugs: a phase III study of the Intergroupe Francophone Du Myelome (IFM/DFCI 2009 trial) [ASH Annual Meeting Abstracts 2015, abstract 391]. American Society of Hematology website. https://ash.confex.com/ash/2015/webprogram/Paper78452.html. Accessed November 10, 2015.
64. P. Moreau, T. Facon, M. Attal, and et al. Comparison of reduced-dose bortezomib plus thalidomide plus dexamethasone (vTD) to bortezomib plus dexamethasone (VD) as induction treatment prior to ASCT in de novo multiple myeloma (MM): results of IFM2007-02 study [abstract] J Clin Oncol 28 15, suppl 2010 8014
65. P. Moreau, H. Pylypenko, S. Grosicki, and et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study [published correction appears in Lancet Oncol. 2011;12(6):522] Lancet Oncol 12 5 2011 431 440
66. A. Palumbo, S. Bringhen, M.V. Mateos, and et al. Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report Blood 125 13 2015 2068 2074
67. L. Benboubker, M.A. Dimopoulos, A. Dispenzieri, et al. FIRST Trial Team Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma N Engl J Med 371 10 2014 906 917
68. A.J. Jakubowiak, D. Dytfeld, K.A. Griffith, and et al. A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma Blood 120 9 2012 1801 1809
69. M.A. Dimopoulos, P. Moreau, A. Palumbo, and et al. Carfilzomib and dexamethasone (Kd) vs bortezomib and dexamethasone (Vd) in patients (pts) with relapsed multiple myeloma (RMM): results from the phase III study ENDEAVOR [abstract] J Clin Oncol 33 suppl 2015 8509
70. M.A. Dimopoulos, E. Terpos, A. Chanan-Khan, and et al. Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group J Clin Oncol 28 33 2010 4976 4984
71. B.L. Burnette, N. Leung, and S.V. Rajkumar Renal improvement in myeloma with bortezomib plus plasma exchange [letter] N Engl J Med 364 24 2011 2365 2366
72. W.F. Clark, A.K. Stewart, G.A. Rock, et al. Canadian Apheresis Group Plasma exchange when myeloma presents as acute renal failure: a randomized, controlled trial [published correction appears in Ann Intern Med. 2007;146(6):471] Ann Intern Med 143 11 2005 777 784
73. W.I. Gonsalves, N. Leung, S.V. Rajkumar, and et al. Improvement in renal function and its impact on survival in patients with newly diagnosed multiple myeloma Blood Cancer J 5 2015 e296
74. J. Bladé, D.H. Vesole, and M. Gertz Transplantation for multiple myeloma: who, when, how often? Blood 102 10 2003 3469 3477
75. A. Kumar, T. Loughran, M. Alsina, B.G. Durie, and B. Djulbegovic Management of multiple myeloma: a systematic review and critical appraisal of published studies Lancet Oncol 4 5 2003 293 304
76. M.A. Gertz, S.M. Ansell, D. Dingli, and et al. Autologous stem cell transplantation in 716 patients with multiple myeloma: low treatment-related mortality, feasibility of outpatient transplant, and impact of a multidisciplinary quality initiative Mayo Clin Proc 83 10 2008 1131 1135
77. 2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myélome 9502 randomized trial Blood 99 3 2002 731 735
78. J.P. Fermand, P. Ravaud, S. Chevret, and et al. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? results of a multicenter sequential randomized clinical trial Blood 92 9 1998 3131 3136
79. T. Facon, J.Y. Mary, J.L. Harousseau, and et al. Front-line or rescue autologous bone marrow transplantation (ABMT) following a first course of high dose melphalan (HDM) in multiple myeloma (MM): preliminary results of a prospective randomized trial (CIAM) protocol [abstract 2729] Blood 88 suppl 1, pt 1 1996 685a
80. B. Barlogie, R. Kyle, K. Anderson, and et al. Comparable survival in multiple myeloma (MM) with high dose therapy (HDT) employing MEL 140 mg/m2 + TBI 12 Gy autotransplants versus standard dose therapy with VBMCP and no benefit from interferon (IFN) maintenance: results of Intergroup Trial S9321 [abstract A-135] Blood 102 11 2003 42a
81. P. Sonneveld, I.G.H. Schmidt-Wolf, B. van der Holt, and et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/GMMG-HD4 trial [published correction appears in J Clin Oncol. 2012;30(29):3654] J Clin Oncol 30 24 2012 2946 2955
82. B. Barlogie, S. Jagannath, D.H. Vesole, and et al. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma Blood 89 3 1997 789 793
83. B. Barlogie, S. Jagannath, K.R. Desikan, and et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma Blood 93 1 1999 55 65
84. M. Attal, J.L. Harousseau, T. Facon, and et al. Single versus double autologous stem-cell transplantation for multiple myeloma N Engl J Med 349 2003 2495 2502
85. M. Cavo, P. Tosi, E. Zamagni, and et al. Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study J Clin Oncol 25 2007 2434 2441
86. J.P. Fermand, C. Alberti, and J.P. Marolleau Single versus tandem high dose therapy (HDT) supported with autologous blood stem cell (ABSC) transplantation using unselected or CD34-enriched ABSC: results of a two by two designed randomized trial in 230 young patients with multiple myeloma (MM) [abstract P10.2.2] Hematol J 4 suppl 1 2003 S59
87. H. Goldschmidt Single vs. tandem autolgous transplantation in multiple myeloma: the GMMG experience [abstract] Hematol J 4 suppl 1 2003 S61
88. A. Krishnan, M.C. Pasquini, B. Logan, et al. Blood Marrow Transplant Clinical Trials Network (BMT CTN) Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial Lancet Oncol 12 13 2011 1195 1203
89. B. Bruno, M. Rotta, F. Patriarca, and et al. A comparison of allografting with autografting for newly diagnosed myeloma N Engl J Med 356 11 2007 1110 1120
90. M. Attal, J.-L. Harousseau, S. Leyvraz, et al. Inter-Groupe Francophone du Myélome (IFM) Maintenance therapy with thalidomide improves survival in patients with multiple myeloma Blood 108 10 2006 3289 3294
91. A. Spencer, H.M. Prince, A.W. Roberts, and et al. Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure J Clin Oncol 27 11 2009 1788 1793
92. M. Attal, V. Lauwers-Cances, G. Marit, et al. IFM Investigators Lenalidomide maintenance after stem-cell transplantation for multiple myeloma N Engl J Med 366 19 2012 1782 1791
93. P.L. McCarthy, K. Owzar, C.C. Hofmeister, and et al. Lenalidomide after stem-cell transplantation for multiple myeloma N Engl J Med 366 19 2012 1770 1781
94. S.V. Rajkumar, G. Gahrton, and P.L. Bergsagel Approach to the treatment of multiple myeloma: a clash of philosophies Blood 118 12 2011 3205 3211
95. S.V. Rajkumar Haematological cancer: lenalidomide maintenance - perils of a premature denouement Nat Rev Clin Oncol 9 7 2012 372 374
96. A.K. Nooka, J.L. Kaufman, S. Muppidi, and et al. Consolidation and maintenance therapy with lenalidomide, bortezomib and dexamethasone (RVD) in high-risk myeloma patients Leukemia 28 3 2014 690 693
97. A. Palumbo, R. Hajek, M. Delforge, et al. MM-015 Investigators Continuous lenalidomide treatment for newly diagnosed multiple myeloma [published correction appears in N Engl J Med. 2012;367(3):285] N Engl J Med 366 19 2012 1759 1769
98. M.A. Gertz, M.Q. Lacy, D.J. Inwards, and et al. Early harvest and late transplantation as an effective therapeutic strategy in multiple myeloma Bone Marrow Transplant 23 3 1999 221 226
99. S.K. Kumar, T.M. Therneau, M.A. Gertz, and et al. Clinical course of patients with relapsed multiple myeloma Mayo Clin Proc 79 7 2004 867 874
100. M. Dimopoulos, A. Spencer, M. Attal, et al. Multiple Myeloma (010) Study Investigators Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma [published correction appears in N Engl J Med. 2009;361(5):544] N Engl J Med 357 21 2007 2123 2132
101. D.M. Weber, C. Chen, R. Niesvizky, et al. Multiple Myeloma (009) Study Investigators Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America N Engl J Med 357 21 2007 2133 2142
102. M. Pineda-Roman, M. Zangari, F. van Rhee, and et al. VTD combination therapy with bortezomib-thalidomide-dexamethasone is highly effective in advanced and refractory multiple myeloma Leukemia 22 7 2008 1419 1427
103. P.G. Richardson, E. Weller, S. Jagannath, and et al. Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma J Clin Oncol 27 34 2009 5713 5719
104. P.G. Richardson, W. Xie, S. Jagannath, and et al. A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma Blood 123 10 2014 1461 1469
105. A.K. Stewart, S.V. Rajkumar, M.A. Dimopoulos, et al. ASPIRE Investigators Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma N Engl J Med 372 2 2015 142 152
106. M.Q. Lacy, S.R. Hayman, M.A. Gertz, and et al. Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma J Clin Oncol 27 30 2009 5008 5014
107. M.Q. Lacy, S.R. Hayman, M.A. Gertz, and et al. Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM) Leukemia 24 11 2010 1934 1939
108. M.Q. Lacy, J.B. Allred, M.A. Gertz, and et al. Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease Blood 118 11 2011 2970 2975
109. J. San Miguel, K. Weisel, P. Moreau, and et al. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial Lancet Oncol 14 11 2013 1055 1066
110. J.F. San-Miguel, V.T.M. Hungria, S.-S. Yoon, and et al. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial [published correction appears in Lancet Oncol. 2015;16(1):e6] Lancet Oncol 15 11 2014 1195 1206
111. T. Hideshima, J.E. Bradner, J. Wong, and et al. Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma Proc Natl Acad Sci U S A 102 24 2005 8567 8572
112. J.F. San-Miguel, P.G. Richardson, A. Günther, and et al. Phase Ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myeloma J Clin Oncol 31 29 2013 3696 3703
113. R.Z. Orlowski, A. Nagler, P. Sonneveld, and et al. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression J Clin Oncol 25 25 2007 3892 3901
114. S. Lonial, B.M. Weiss, S.Z. Usmani, and et al. Phase II study of daratumumab (DARA) monotherapy in patients with ≥ 3 lines of prior therapy or double refractory multiple myeloma (MM): 54767414MMY2002 (Sirius) [abstract] J Clin Oncol 33 15, suppl 2015 LBA8512
115. S. Lonial, M. Dimopoulos, A. Palumbo, et al. ELOQUENT-2 Investigators Elotuzumab therapy for relapsed or refractory multiple myeloma N Engl J Med 373 7 2015 621 631
116. Moreau P, Masszi T, Grzasko N, et al. Ixazomib, an investigational oral proteasome inhibitor (PI), in combination with lenalidomide and dexamethasone (IRd), significantly extends progression-free survival (PFS) for patients (Pts) with relapsed and/or refractory multiple myeloma (RRMM): the phase 3 Tourmaline-MM1 Study (NCT01564537) [ASH Annual Meeting Abstracts 2015, abstract 727]. American Society of Hematology website. https://ash.confex.com/ash/2015/webprogram/Paper79829.html. Accessed November 11, 2015.
117. R. Gucalp, R. Theriault, I. Gill, and et al. Treatment of cancer-associated hypercalcemia: double-blind comparison of rapid and slow intravenous infusion regimens of pamidronate disodium and saline alone Arch Intern Med 154 17 1994 1935 1944
118. P. Major, A. Lortholary, J. Hon, and et al. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials J Clin Oncol 19 2 2001 558 567
119. J.R. Berenson, A. Lichtenstein, L. Porter, et al. Myeloma Aredia Study Group Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group [see comments] N Engl J Med 334 8 1996 488 493
120. J.R. Berenson, L.S. Rosen, A. Howell, and et al. Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases [published correction appears in Cancer. 2001;91(10):1956] Cancer 91 7 2001 1191 1200
121. L.S. Rosen, D. Gordon, M. Kaminski, and et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastatses in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double blind, comparative trial Cancer J 7 5 2001 377 387
122. J.R. Berenson, B.E. Hillner, R.A. Kyle, et al. American Society of Clinical Oncology Bisphosphonates Expert Panel American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma J Clin Oncol 20 17 2002 3719 3736
123. G.J. Morgan, F.E. Davies, W.M. Gregory, et al. National Cancer Research Institute Haematological Oncology Clinical Study Group First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial Lancet 376 9757 2010 1989 1999
124. D.R. Fourney, D.F. Schomer, R. Nader, and et al. Percutaneous vertebroplasty and kyphoplasty for painful vertebral body fractures in cancer patients J Neurosurg 98 1 suppl 2003 21 30
125. D.H. Vesole, M.M. Oken, C. Heckler, et al. University of Rochester Cancer Center and the Eastern Cooperative Oncology Group Oral antibiotic prophylaxis of early infection in multiple myeloma: a URCC/ECOG randomized phase III study Leukemia 26 12 2012 2517 2520
126. M.M. Oken, C. Pomeroy, D. Weisdorf, and J.M. Bennett Prophylactic antibiotics for the prevention of early infection in multiple myeloma Am J Med 100 6 1996 624 628
127. M.A. Gertz, and R.A. Kyle Hyperviscosity syndrome J Intensive Care Med 10 3 1995 128 141
128. S.V. Rajkumar, O. Landgren, and M.V. Mateos Smoldering multiple myeloma Blood 125 20 2015 3069 3075
129. M. Hjorth, L. Hellquist, E. Holmberg, B. Magnusson, S. Rödjer, and J. Westin Initial versus deferred melphalan-prednisone therapy for asymptomatic multiple myeloma stage I - a randomized study Eur J Haematol 50 2 1993 95 102
130. G. Grignani, P.G. Gobbi, R. Formisano, and et al. A prognostic index for multiple myeloma Br J Cancer 73 9 1996 1101 1107
131. M.-V. Mateos, M.-T. Hernández, P. Giraldo, and et al. Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma N Engl J Med 369 5 2013 438 447